Lv2
170 积分 2022-09-21 加入
Optimizing anti-CD3 affinity for effective T cell targeting against tumor cells
17小时前
已完结
Antibody-oligonucleotide conjugates in cancer therapy: Potential and Promise
2天前
已完结
Research progress and development strategies of antibody-oligonucleotide conjugates
2天前
已完结
Just scratching the surface: novel treatment approaches for multiple myeloma targeting cell membrane proteins
1个月前
已完结
Clinical Immunology
3个月前
已关闭
The hallmarks of oncogenic signaling: from pathways to resistance in cancer therapy
5个月前
已完结
Current Trends in Immuno-Oncology
8个月前
已完结
Navigating established and emerging biomarkers for immune checkpoint inhibitor therapy
8个月前
已完结
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
9个月前
已完结
皖公网安备34019202002308
